Jane Street
NTLA icon

Jane Street’s Intellia Therapeutics NTLA Stock Holding History

Jane Street’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$226K Sell
13,350
-371,607
-97% -$5.2M ﹤0.01% 9840
2026
Q1 		$4.94M Buy
384,957
+52,486
+16% +$669K ﹤0.01% 3540
2025
Q4 		$2.99M Buy
332,471
+132,372
+66% +$1.82M ﹤0.01% 4045
2025
Q3 		$3.46M Sell
200,099
-12,731
-6% -$157K ﹤0.01% 3995
2025
Q2 		$2M Buy
212,830
+64,795
+44% +$532K ﹤0.01% 4416
2025
Q1 		$1.05M Sell
148,035
-107,221
-42% -$1.08M ﹤0.01% 5477
2024
Q4 		$2.98M Buy
255,256
+19,129
+8% +$299K ﹤0.01% 3457
2024
Q3 		$4.85M Sell
236,127
-9,299
-4% -$214K ﹤0.01% 2910
2024
Q2 		$5.49M Buy
245,426
+151,594
+162% +$3.61M ﹤0.01% 2834
2024
Q1 		$2.58M Sell
93,832
-110,453
-54% -$3.07M ﹤0.01% 3666
2023
Q4 		$6.23M Buy
204,285
+116,308
+132% +$3.34M ﹤0.01% 2554
2023
Q3 		$2.78M Sell
87,977
-116,862
-57% -$4.53M ﹤0.01% 3492
2023
Q2 		$8.35M Buy
204,839
+156,638
+325% +$6.35M ﹤0.01% 2110
2023
Q1 		$1.8M Sell
48,201
-12,822
-21% -$503K ﹤0.01% 4011
2022
Q4 		$2.13M Buy
61,023
+30,092
+97% +$1.43M ﹤0.01% 3777
2022
Q3 		$1.73M Sell
30,931
-9,119
-23% -$566K ﹤0.01% 4442
2022
Q2 		$2.07M Buy
40,050
+18,503
+86% +$940K ﹤0.01% 4096
2022
Q1 		$1.57M Sell
21,547
-13,367
-38% -$1.13M ﹤0.01% 5223
2021
Q4 		$4.13M Buy
34,914
+15,153
+77% +$1.9M ﹤0.01% 3156
2021
Q3 		$2.65M Sell
19,761
-31,938
-62% -$4.84M ﹤0.01% 3906
2021
Q2 		$8.37M Sell
51,699
-6,578
-11% -$512K ﹤0.01% 1921
2021
Q1 		$4.68M Sell
58,277
-47,034
-45% -$3.16M ﹤0.01% 2500
2020
Q4 		$5.73M Buy
105,311
+73,549
+232% +$2.67M ﹤0.01% 1970
2020
Q3 		$631K Buy
31,762
+20,584
+184% +$429K ﹤0.01% 4810
2020
Q2 		$235K Buy
+11,178
New +$190K ﹤0.01% 6175

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Jane Street's NTLA Position: Q2 2026 in Review

Jane Street reduced its Intellia Therapeutics (NTLA) stake by 97% in Q2 2026, selling an estimated $5.2M and leaving 13,350 shares worth $226K. The position accounts for ﹤0.01% of the portfolio, ranked #9840.

Jane Street first reported a position in NTLA in Q2 2020 and has held it in 25 quarters since. The position peaked at $8.37M in Q2 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Jane Street held 13,350 shares of Intellia Therapeutics worth $226K as of Q2 2026.
  • Jane Street sold 371,607 Intellia Therapeutics shares in Q2 2026, an estimated $5.2M.
  • Intellia Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #9840 holding.
  • Jane Street first reported a position in Intellia Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Jane Street's Intellia Therapeutics position peaked at $8.37M in Q2 2021.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.